Kite CEO Christi Shaw to de­part Gilead CAR-T unit

Christi Shaw will leave her post as CEO of Gilead’s Kite Phar­ma at the end of this quar­ter, Gilead said Fri­day morn­ing.

Shaw led the CAR-T cell ther­a­py com­pa­ny since 2019, more than a year af­ter Gilead swooped in to buy the biotech for about $12 bil­lion.

She over­saw a cell ther­a­py mak­er that de­liv­ered its CAR-T treat­ments, Yescar­ta and Tecar­tus, to about 13,000 pa­tients in more than 20 coun­tries fol­low­ing the for­mer’s first ap­proval in 2017, Gilead said. The bio­phar­ma is one of a few to have so far re­ceived FDA clear­ance for au­tol­o­gous cell ther­a­pies, as the in­dus­try tries ex­pand­ing the ther­a­peu­tic tools’ scope from blood can­cers to oth­er ar­eas of on­col­o­gy.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN